Palatin Technologies (PTN) Free Cash Flow (2010 - 2026)
Palatin Technologies' (PTN) quarterly Free Cash Flow came in at -$4.5 million in Q1 2026, up 16.79% YoY from -$3.8 million in Q1 2025, and up 7.31% on a QoQ basis from -$4.8 million in Q4 2025.
Palatin Technologies (PTN) Free Cash Flow (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 17 years of Free Cash Flow data on file, last reported at -$4.5 million in Q1 2026.
- Quarterly Free Cash Flow rose 16.79% year-over-year to -$4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.0 million (up 36.82% YoY) and the FY2025 annual result came in at -$21.3 million, up 32.37% from the prior year.
- Free Cash Flow advanced to -$4.5 million in Q1 2026, from -$4.8 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$1.5 million in Q1 2023 to a low of -$10.5 million in Q4 2023.
- A 5-year average of -$6.5 million and a median of -$6.5 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 3253.32% — and 2023, when it surged 84.06%.
- Tracing PTN's Free Cash Flow over 5 years: stood at -$9.8 million in 2022, then declined by 7.29% to -$10.5 million in 2023, then soared by 53.9% to -$4.8 million in 2024, then rose by 0.83% to -$4.8 million in 2025, then grew by 7.31% to -$4.5 million in 2026.
- The last three Free Cash Flow figures came in at -$4.5 million (Q1 2026), -$4.8 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | -4.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.46 Mn |
| Mar 31, 2026 | -4.46 Mn |
| Dec 31, 2025 | -4.81 Mn |
| Dec 31, 2025 | -4.81 Mn |
| Sep 30, 2025 | -1.62 Mn |
| Sep 30, 2025 | -1.62 Mn |
| Jun 30, 2025 | -4.09 Mn |
| Jun 30, 2025 | -4.09 Mn |
| Mar 31, 2025 | -5.35 Mn |
| Mar 31, 2025 | -5.35 Mn |
| Dec 31, 2024 | -4.85 Mn |
| Dec 31, 2024 | -4.85 Mn |
| Sep 30, 2024 | -7.02 Mn |
| Sep 30, 2024 | -7.02 Mn |
| Jun 30, 2024 | -6.48 Mn |
| Jun 30, 2024 | -6.48 Mn |
| Mar 31, 2024 | -8.61 Mn |
| Mar 31, 2024 | -8.61 Mn |
| Dec 31, 2023 | -10.51 Mn |
| Dec 31, 2023 | -10.51 Mn |